Sugar modified pyrimido[4,5-

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. An insight into the recent developments in anti-infective potential of indole and associated hybrids.Journal of molecular structure · 2022
   Review
2. Triterpenoid-PEG Ribbons Targeting Selectivity in Pharmacological Effects.Biomedicines · 2021
   Article
3. In silico DFT study, molecular docking, and ADMET predictions of cytidine analogs with antimicrobial and anticancer properties.In silico pharmacology · 2021
   Article
4. Indole - a promising pharmacophore in recent antiviral drug discovery.RSC medicinal chemistry · 2020
   Review
5. Enzymatic synthesis of nucleoside analogues from uridines and vinyl esters in a continuous-flow microreactor.RSC advances · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract